M
Murdo Ferguson
Researcher at Dalhousie University
Publications - 16
Citations - 478
Murdo Ferguson is an academic researcher from Dalhousie University. The author has contributed to research in topics: Vaccination & AS03. The author has an hindex of 9, co-authored 16 publications receiving 379 citations.
Papers
More filters
Journal ArticleDOI
Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
Cosette M. Wheeler,S. Rachel Skinner,S. Rachel Skinner,M. Rowena Del Rosario-Raymundo,Suzanne M. Garland,Archana Chatterjee,Eduardo Lazcano-Ponce,Jorge Salmerón,Shelly A. McNeil,Jack T. Stapleton,Céline Bouchard,Mark G. Martens,Deborah Money,Swee Chong Quek,Barbara Romanowski,Carlos S. Vallejos,Bram ter Harmsel,V. N. Prilepskaya,Kah Leng Fong,Henry C Kitchener,Galina Minkina,Yong Kuei Timothy Lim,Tanya Stoney,Nahida Chakhtoura,Margaret E. Cruickshank,Alevtina Savicheva,Daniel da Silva,Murdo Ferguson,Anco Molijn,Wim Quint,Karin Hardt,Dominique Descamps,P.V. Suryakiran,Naveen Karkada,Brecht Geeraerts,Gary Dubin,Frank Struyf +36 more
TL;DR: The VIVIANE study of the HPV 16/18 AS04-adjuvanted vaccine in adult women after 7 years of follow-up continues to protect against infections, cytological abnormalities, and lesions associated with HPV 15/18 and CIN1+ irrespective of HPV type, and infection with non-vaccine types HPV 31 and HPV 45.
Journal ArticleDOI
Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study.
Barbara Romanowski,Tino F. Schwarz,Linda Ferguson,Murdo Ferguson,Klaus Peters,Marc Dionne,Karin Schulze,Brian Ramjattan,Peter Hillemanns,Ulrich Behre,P.V. Suryakiran,Florence Thomas,Frank Struyf +12 more
TL;DR: Investigation of the immunogenicity and safety of 2-dose schedules of the HPV-16/18 AS04-adjuvanted vaccine found that a 2D schedule could facilitate implementation of HPV vaccination programs and improve vaccine coverage and series completion rates.
Journal ArticleDOI
Safety and Long-term Humoral Immune Response in Adults After Vaccination With an H1N1 2009 Pandemic Influenza Vaccine With or Without AS03 Adjuvant
Murdo Ferguson,George Risi,Matthew Davis,Eric Sheldon,Mira Baron,Ping Li,Miguel Madariaga,Louis Fries,Olivier Godeaux,David W. Vaughn +9 more
TL;DR: A single dose of the 3.75-μg HA AS03(A)-adjuvanted H1N1 2009 influenza vaccine was highly immunogenic in both age strata (18-64 and >64 years), inducing long-term persistence of the immune response until at least 6 months after dose 1.
Journal ArticleDOI
Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults
Anuradha Madan,Nathan Segall,Murdo Ferguson,Louise Frenette,Robin Kroll,Damien Friel,Jyoti Soni,Ping Li,Bruce L. Innis,Anne Schuind +9 more
TL;DR: Two doses of AS03-adjuvanted H7N9 vaccine were well tolerated and induced a robust antibody response at antigen-sparing doses in healthy adults and met regulatory acceptance criteria.
Journal ArticleDOI
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
Terry Nolan,María Elena Santolaya,Ferdinandus de Looze,Helen Marshall,Peter Richmond,Sam Henein,Paul Rheault,Ken Heaton,Kirsten P Perrett,Hartley Garfield,Anil Gupta,Murdo Ferguson,Diego D'Agostino,Daniela Toneatto,Miguel O'Ryan +14 more
TL;DR: A more robust immune response after booster compared to a first dose in vaccine-naïve individuals, showed effective priming in an adolescent/young adult population.